Probabilistic Boolean Modeling of Pre‐clinical Tumor Models for Biomarker Identification in Cancer Drug Development

2021 ◽  
Vol 1 (10) ◽  
Author(s):  
Noah E. Berlow
Keyword(s):  
Drug Development ◽  
Cancer Drug ◽  
Tumor Models ◽  
Biomarker Identification ◽  
Boolean Modeling

scholarly journals PROSPECTIVE AND RETROSPECTIVE ANIMAL MODEL USED IN THE PHARMACOLOGICAL SCREENING OF ANTI-CANCER DRUG

2018 ◽  
Vol 10 (4) ◽  
pp. 13
Author(s):  
Shamima Nasreen Ahmed ◽  
Biswajit Das ◽  
Jashabir Chakraborty
Keyword(s):  
Drug Development ◽  
Anticancer Drug ◽  
Drug Screening ◽  
Rapid Development ◽  
The Body ◽  
Cytotoxic Agents ◽  
Cancer Drug ◽  
Tumor Models ◽  
Preclinical Screening ◽  
Anticancer Drug Development

Cancer is a disease characterized by uncontrolled proliferation of cells that have transformed from the normal cells of the body. The widely used cancer drugs suffers from the drawback of high toxicity not within the reach of a common man. This urgently necessitating the screening of these compounds. This review focuses on the major contributions of preclinical screening models to anticancer drug development over the years till recent times, from the empirical drug screening of cytotoxic agents against uncharacterized tumor models to the target-orientated drug screening of agents with defined mechanisms of action,, a general transition has been observed. The newer approaches to anticancer drug development involve the molecular characterization of models along with an appreciation of the pharmacodynamics and pharmacokinetic properties of compounds [e. g., the US National Cancer Institute (NCI) in vitro 60-cell line panel, hollow fibre assay, and s. c. xenograft]. In vivo tumor models including orthotopic, metastatic, and genetically engineered mouse models are also reviewed. The preclinical screening efforts of the European are also included. In 2015 with the rapid development of cancer modeling in zebrafish, great opportunities exist for chemical screens to find anticancer drug since 1970 the European Organisation for Research and Treatment of Cancer and Cancer Research UK, have been collaborating with the NCI in the acquisition and screening of compounds.

Diverse thiophenes as scaffolds in anti-cancer drug development: A concise review

2020 ◽  
Vol 20 ◽  
Author(s):  
Neha V. Bhilare ◽  
Pratibha B. Auti ◽  
Vinayak S. Marulkar ◽  
Vilas J. Pise
Keyword(s):  
Drug Development ◽  
Anticancer Agents ◽  
Heterocyclic Ring ◽  
Biologically Active Compounds ◽  
Biologically Active ◽  
Cancer Drug ◽  
Active Compounds ◽  
Natural Origin ◽  
Concise Review ◽  
Anti Cancer

: Thiophenes are one among the abundantly found heterocyclic ring systems in many biologically active compounds. Moreover various substituted thiophenes exert numerous pharmacological actions on account of their isosteric resemblance with compounds of natural origin thus rendering them with diverse actions like antibacterial, antifungal, antiviral, anti-inflammatory, analgesic, antiallergic, hypotensives etc.. In this review we specifically explore the chemotherapeutic potential of variety of structures consisting of thiophene scaffolds as prospective anticancer agents.

Prevascularized, Co-Culture Model for Breast Cancer Drug Development

2012 ◽  
Author(s):  
Lauren Marshall ◽  
Isabel Löwstedt ◽  
Paul Gatenholm ◽  
Joel Berry
Keyword(s):  
Breast Cancer ◽  
Drug Development ◽  
Three Dimensional ◽  
Human Tumor ◽  
3D Models ◽  
Cancer Drug ◽  
Cancer Therapies ◽  
Anti Cancer

The objective of this study was to create 3D engineered tissue models to accelerate identification of safe and efficacious breast cancer drug therapies. It is expected that this platform will dramatically reduce the time and costs associated with development and regulatory approval of anti-cancer therapies, currently a multi-billion dollar endeavor [1]. Existing two-dimensional (2D) in vitro and in vivo animal studies required for identification of effective cancer therapies account for much of the high costs of anti-cancer medications and health insurance premiums borne by patients, many of whom cannot afford it. An emerging paradigm in pharmaceutical drug development is the use of three-dimensional (3D) cell/biomaterial models that will accurately screen novel therapeutic compounds, repurpose existing compounds and terminate ineffective ones. In particular, identification of effective chemotherapies for breast cancer are anticipated to occur more quickly in 3D in vitro models than 2D in vitro environments and in vivo animal models, neither of which accurately mimic natural human tumor environments [2]. Moreover, these 3D models can be multi-cellular and designed with extracellular matrix (ECM) function and mechanical properties similar to that of natural in vivo cancer environments [3].

Modeling human carcinomas: Physiologically relevant 3D models to improve anti-cancer drug development

2014 ◽  
Vol 79-80 ◽  
pp. 50-67 ◽  
Author(s):  
Christine Unger ◽  
Nina Kramer ◽  
Angelika Walzl ◽  
Martin Scherzer ◽  
Markus Hengstschläger ◽  
...  
Keyword(s):  
Drug Development ◽  
3D Models ◽  
Cancer Drug ◽  
Anti Cancer ◽  
Human Carcinomas

scholarly journals Prospect of reprogramming replication licensing for cancer drug development

2021 ◽  
Vol 136 ◽  
pp. 111190 ◽  
Author(s):  
Isaac Kyei Barffour ◽  
Desmond Omane Acheampong
Keyword(s):  
Drug Development ◽  
Cancer Drug

Characterization of cannabinoid receptors expressed in Ewing sarcoma TC-71 and A-673 cells as potential targets for anti-cancer drug development

Life Sciences ◽  
2021 ◽  
Vol 285 ◽  
pp. 119993
Author(s):  
Amal M. Shoeib ◽  
Azure L. Yarbrough ◽  
Benjamin M. Ford ◽  
Lirit N. Franks ◽  
Alicja Urbaniak ◽  
...  
Keyword(s):  
Drug Development ◽  
Ewing Sarcoma ◽  
Cannabinoid Receptors ◽  
Cancer Drug ◽  
Anti Cancer

Toward the Broad Adoption of 3D Tumor Models in the Cancer Drug Pipeline

2015 ◽  
Vol 1 (10) ◽  
pp. 877-894 ◽  
Author(s):  
Megan C. Cox ◽  
Laura M. Reese ◽  
Lissett R. Bickford ◽  
Scott S. Verbridge
Keyword(s):  
Cancer Drug ◽  
Tumor Models ◽  
Drug Pipeline
Sign in / Sign up

Export Citation Format

Share Document